Developer docs
API playgroundTry for free, no card

Search company profiles

dNovo Bio

Full company profile

uuid0003a4c

Namestring
dNovo Bio
Legal namestring
dNovo
Websiteurl
dnovobio.com
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

dNovo Bio is a preclinical biotechnology company developing direct reprogramming technology to convert a patient's own skin, blood, or fat cells into autologous hair stem cells and dermal papilla cells for permanent treatment of male pattern baldness and age-associated hair loss.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Jose, United States
HQ citystring
San Jose
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, stem cell therapy, hair loss treatment, direct reprogramming, biotech therapeutics
Industry1 code
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Hair Stem Cell Treatment
TypeOne Time License
Description

Pre-revenue biotech company developing a permanent hair loss cure through personalized hair stem cell generation. Revenue model will likely involve medical treatment/procedure fees for cell collection, reprogramming, and transplantation.

dnovobio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

dNovo Bio develops a proprietary direct reprogramming technology that converts a patient's own cells (skin, blood, or fat) into personalized hair stem cells and dermal papilla cells to permanently treat hair loss caused by DHT-induced male patterned baldness and age-associated hair miniaturization. The planned treatment is administered at the company's onsite facility through a five-step process involving cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, and seeding onto the scalp, with hair growth expected within 1-3 months. The company is pre-commercial and operates in stealth-mode development with animal-model validation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Hair growth visible in 1-3 months after treatment
+1 more record
Product overview1 text field

dNovo Bio is a biotech company offering a single unified therapeutic approach centered on its proprietary direct reprogramming technology. The core offering converts a patient's own cells (from skin, blood, or fat) into personalized hair stem cells and dermal papilla cells, which are then transplanted to treat hair loss at its root cause. The five-step process involves cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, seeding onto the scalp, with visible hair growth expected in 1-3 months. The company operates from its Silicon Valley facility and focuses exclusively on permanent hair loss treatment through stem cell regeneration rather than temporary solutions.

Product and service1 record
1Personalized Hair Stem Cell Therapy
CategoryRegenerative Medicine / Hair Loss Treatment
Description

Pre-commercial planned medical service that addresses the root cause of hair loss (hair stem cell loss) by collecting a small skin sample or a few drops of blood from the patient, applying proprietary direct reprogramming factors to generate personalized hair stem cells and dermal papilla cells, and transplanting them onto the scalp. Designed for individuals with DHT-induced male patterned baldness and age-associated hair miniaturization, offering a permanent regenerative solution compatible with the patient's immune system.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Stemson is developing iPSC-derived hair follicle cells to treat hair loss, the most direct competitor to dNovo in cellular hair regeneration; both pursue patient-derived reprogrammed cells rather than transplants or topicals.

TypeDirect peer
Description

RepliCel is developing autologous cell therapies (RCH-01 dermal sheath cup cells) for hair loss, making it a direct comparator in the autologous hair cell therapy space alongside dNovo.

TypeDirect peer
Description

Histogen is developing regenerative treatments for hair loss using proprietary cell-conditioned media and HSC-derived stimulators, targeting the same hair loss indication via cell-based approaches.

4Turn Biotechnologies
TypeDirect peer
Description

Turn Bio develops mRNA-based direct reprogramming (epigenetic reprogramming) to restore youthful cell function across multiple tissues, sharing dNovo's core scientific premise of direct cellular reprogramming for age-related conditions.

5AgeX Therapeutics
TypeEmerging player
Description

AgeX is a clinical-stage company focused on cellular rejuvenation and induced tissue regeneration (iTR) technology, targeting age-related degenerative conditions with a related but broader platform than dNovo's hair focus.

TypeBroad incumbent
Description

Biosplice is a well-funded late-stage biotech developing Wnt-pathway small molecules (lorecivivint and hair loss candidate) that represent a competing mechanism-of-action for hair regeneration versus dNovo's cell therapy approach.

TypeBroad incumbent
Description

Aderans is a global hair restoration incumbent (wig/hairpiece plus cell-based R&D via subsidiary) pursuing hair regeneration through autologous cell technologies and tissue engineering, comparable as a broader incumbent in the hair regeneration space.

8Shiseido
TypeBroad incumbent
Description

Shiseido operates a hair science research program (Replicel partnership history, hair growth factor research) within its broader beauty R&D, making it a large incumbent researching regenerative hair solutions with relevant scientific overlap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

dNovo Bio

Regenerative Medicinednovobio.com

dNovo Bio is a preclinical biotechnology company developing direct reprogramming technology to convert a patient's own skin, blood, or fat cells into autologous hair stem cells and dermal papilla cells for permanent treatment of male pattern baldness and age-associated hair loss.

dNovo Bio firmographics

Firmographics
Name
dNovo Bio
Legal name
dNovo
Website
https://dnovobio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
dNovo Bio is a preclinical biotechnology company developing direct reprogramming technology to convert a patient's own skin, blood, or fat cells into autologous hair stem cells and dermal papilla cells for permanent treatment of male pattern baldness and age-associated hair loss.
Ownership category
akta.pro rank

dNovo Bio industry classification

Industry
Product category
Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Regenerative medicine
  • Stem cell therapy
  • Hair loss treatment
  • Direct reprogramming
  • Biotech therapeutics

Where dNovo Bio is headquartered

Location

Headquarters

HQ city
San Jose
HQ country
United States
HQ region
North America

Offices1 record

Markets served

dNovo Bio business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Hair Stem Cell Treatment: Pre-revenue biotech company developing a permanent hair loss cure through personalized hair stem cell generation. Revenue model will likely involve medical treatment/procedure fees for cell collection, reprogramming, and transplantation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

dNovo Bio product offering

Product offering

Core offering

dNovo Bio develops a proprietary direct reprogramming technology that converts a patient's own cells (skin, blood, or fat) into personalized hair stem cells and dermal papilla cells to permanently treat hair loss caused by DHT-induced male patterned baldness and age-associated hair miniaturization. The planned treatment is administered at the company's onsite facility through a five-step process involving cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, and seeding onto the scalp, with hair growth expected within 1-3 months. The company is pre-commercial and operates in stealth-mode development with animal-model validation.

Product overview

dNovo Bio is a biotech company offering a single unified therapeutic approach centered on its proprietary direct reprogramming technology. The core offering converts a patient's own cells (from skin, blood, or fat) into personalized hair stem cells and dermal papilla cells, which are then transplanted to treat hair loss at its root cause. The five-step process involves cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, seeding onto the scalp, with visible hair growth expected in 1-3 months. The company operates from its Silicon Valley facility and focuses exclusively on permanent hair loss treatment through stem cell regeneration rather than temporary solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Personalized Hair Stem Cell Therapy Pre-commercial planned medical service that addresses the root cause of hair loss (hair stem cell loss) by collecting a small skin sample or a few drops of blood from the patient, applying proprietary direct reprogramming factors to generate personalized hair stem cells and dermal papilla cells, and transplanting them onto the scalp. Designed for individuals with DHT-induced male patterned baldness and age-associated hair miniaturization, offering a permanent regenerative solution compatible with the patient's immune system.

Quantifiable outcome

  • Hair growth visible in 1-3 months after treatment
  • +1 more outcomes

Companies that use dNovo Bio

Customer profile

Segments2 records

Ideal customer profiles1 record

dNovo Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

dNovo Bio partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

dNovo Bio competitors and assessment

Company assessment

Direct peers

  • Stemson Therapeutics: Stemson is developing iPSC-derived hair follicle cells to treat hair loss, the most direct competitor to dNovo in cellular hair regeneration; both pursue patient-derived reprogrammed cells rather than transplants or topicals.
  • RepliCel Life Sciences: RepliCel is developing autologous cell therapies (RCH-01 dermal sheath cup cells) for hair loss, making it a direct comparator in the autologous hair cell therapy space alongside dNovo.
  • Histogen: Histogen is developing regenerative treatments for hair loss using proprietary cell-conditioned media and HSC-derived stimulators, targeting the same hair loss indication via cell-based approaches.
  • Turn Biotechnologies: Turn Bio develops mRNA-based direct reprogramming (epigenetic reprogramming) to restore youthful cell function across multiple tissues, sharing dNovo's core scientific premise of direct cellular reprogramming for age-related conditions.

Emerging players

  • AgeX Therapeutics: AgeX is a clinical-stage company focused on cellular rejuvenation and induced tissue regeneration (iTR) technology, targeting age-related degenerative conditions with a related but broader platform than dNovo's hair focus.

Broad incumbents

  • Biosplice (formerly Samumed): Biosplice is a well-funded late-stage biotech developing Wnt-pathway small molecules (lorecivivint and hair loss candidate) that represent a competing mechanism-of-action for hair regeneration versus dNovo's cell therapy approach.
  • Aderans Company: Aderans is a global hair restoration incumbent (wig/hairpiece plus cell-based R&D via subsidiary) pursuing hair regeneration through autologous cell technologies and tissue engineering, comparable as a broader incumbent in the hair regeneration space.
  • Shiseido: Shiseido operates a hair science research program (Replicel partnership history, hair growth factor research) within its broader beauty R&D, making it a large incumbent researching regenerative hair solutions with relevant scientific overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

dNovo Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

dNovo Bio leadership team

Management profile

Number of profiles

Profiles1 record

dNovo Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

dNovo Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about dNovo Bio

What does dNovo Bio do?

dNovo Bio develops a proprietary direct reprogramming technology that converts a patient's own cells (skin, blood, or fat) into personalized hair stem cells and dermal papilla cells to permanently treat hair loss caused by DHT-induced male patterned baldness and age-associated hair miniaturization. The planned treatment is administered at the company's onsite facility through a five-step process involving cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, and seeding onto the scalp, with hair growth expected within 1-3 months. The company is pre-commercial and operates in stealth-mode development with animal-model validation.

Is dNovo Bio a public or private company?

dNovo Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was dNovo Bio founded?

dNovo Bio was founded in 2018. It employs 1 to 10 people.

Where is dNovo Bio based?

dNovo Bio is headquartered in San Jose, United States, in the North America region.

How does dNovo Bio make money?

One revenue line is on record: hair Stem Cell Treatment.

Who are dNovo Bio's main competitors?

Direct peers on record are Stemson Therapeutics, RepliCel Life Sciences, Histogen and Turn Biotechnologies. AgeX Therapeutics is listed as an emerging player. Broad incumbents are Biosplice (formerly Samumed), Aderans Company and Shiseido.

Does dNovo Bio have an API?

No public API is recorded for dNovo Bio.

What industry is dNovo Bio in?

dNovo Bio's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogdNovo Emerges From Stealth With Its Potential Cure for Hair LossdNovo Inc. emerged from stealth and announced $2.7M in seed funding from Y Combinator, Felicis Ventures, Soma Capital, and others. The company's direct reprogramming system converts skin cells into induced hair stem cells, which produced hair in a mouse model. dNovo is optimizing its platform and seeking partners to advance the technology.VC News DailydNovo Emerges From Stealth with $2.7M SeeddNovo, a startup developing a cure for hair loss using personalized stem cells, has emerged from stealth and secured $2.7 million in seed funding. The investment was provided by Y Combinator, Felicis Ventures, Soma Capital, and Yintai Investment Company LLC to support the development of its proprietary direct reprogramming system.FinSMEsdNovo Raises $2.7M In Seed FundingdNovo Inc. has emerged from stealth with $2.7 million in seed funding to support the development of its proprietary direct reprogramming system for personalized hair stem cells. The company, led by CEO Dr. Ernesto Lujan, aims to use these funds to expand its research efforts in treating hair loss conditions such as male pattern baldness.MIT Technology ReviewGoing bald? Lab-grown hair cells could be on the wayStartups like dNovo and Stemson are using genetic reprogramming to create hair-forming cells from ordinary cells, with dNovo showing a mouse sprouting human hair after a transplant. The technology could treat the underlying cause of hair loss, but more research is needed before clinical use.